Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new way to treat multiple myeloma, a type of cancer that has come back or not responded to treatment. They want to see if adding a drug called panobinostat to a combination of three other drugs (daratumumab, bortezomib, and dexamethasone) can stop the cancer from growing. Panobinostat may work by stopping the growth of new blood vessels that the cancer needs to survive. The scientists hope that this four-drug treatment will work better than the current treatments for this type of cancer.
Scientists are testing a new way to treat multiple myeloma, a type of cancer that has come back or not responded to treatment. They want to see if adding a drug called panobinostat to a combination of three other drugs (daratumumab, bortezomib, and dexamethasone) can stop the cancer from growing. Panobinostat may work by stopping the growth of new blood vessels that the cancer needs to survive. The scientists hope that this four-drug treatment will work better than the current treatments for this type of cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: